Gene Expression Profiling of the PPAR-alpha Agonist Ciprofibrate in the Cynomolgus Monkey Liver
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Fibrates, such as ciprofibrate, fenofibrate, and clofibrate, are peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists that have been in clinical use for many decades for treatment of dyslipidemia. When mice and rats are given PPARalpha agonists, these drugs cause hepatic peroxisome proliferation, hypertrophy, hyperplasia, and eventually hepatocarcinogenesis. Importantly, primates are relatively refractory to these effects; however, the mechanisms for the species differences are not clearly understood. Cynomolgus monkeys were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips. Strong upregulation of many genes relating to fatty acid metabolism and mitochondrial oxidative phosphorylation was observed; this reflects the known pharmacology and activity of the fibrates. In addition, (1) many genes related to ribosome and proteasome biosynthesis were upregulated, (2) a large number of genes downregulated were in the complement and coagulation cascades, (3) a number of key regulatory genes, including members of the JUN, MYC, and NFkappaB families were downregulated, which appears to be in contrast to the rodent, where JUN and MYC are reported to upregulated after PPARalpha agonist treatment, (4) no transcriptional signal for DNA damage or oxidative stress was observed, and (5) transcriptional signals consistent with an anti-proliferative and a pro-apoptotic effect were seen. We also compared the primate data to literature reports of hepatic transcriptional profiling in PPARalpha-treated rodents, which showed that the magnitude of induction in beta-oxidation pathways was substantially greater in the rodent than the primate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein degradation and protection against misfolded or damaged proteins.
Goldberg, A. L. (2003) · Nature · doi:10.1038/nature02263 · Cited by 2,088 · cited 1×
“The 26S proteasome is part of the ubiquitin–proteasome pathway and removes aged, damaged, and misfolded proteins in mammalian cells (Goldberg, 2003).”
BackgroundYuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884 · cited 1×
“IκB, a key regulator of NFκB, may be a key mediator in insulin resistance as was suggested by recent work demonstrating that high doses of salicylates, which inhibit IκB activation, reversed hyperglycemia, hyperinsulinemia, and dyslipidemia in obese rodents by sensitizing insulin signaling (Yuan et al. 2001).”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345 · cited 1×
“a role in the inflammatory response was the demonstration that PPARa agonists increase the degradation of the pro-inflammatory leukotriene B4 (LTB4) (Devchand et al., 1996).”
BackgroundDelerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Peroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755 · cited 1×
“A general mechanism by which PPARα agonists may exhibit anti-inflammatory action appears to be by antagonizing nuclear factor-κB (NFκB) and activating protein-1 (AP-1) (Delerive et al. 1999; Delerive et al. 2001).”
Background
Cited by
Hall, A. P., Elcombe, C. R., Foster, J. R., Harada, T., Kaufmann, W., Knippel, A., Küttler, K., Malarkey, D. E., Maronpot, R. R., Nishikawa, A., et al. (2012) · Toxicologic Pathology · doi:10.1177/0192623312448935 · Cited by 427
Rodricks, J. V., Swenberg, J. A., Borzelleca, J. F., Maronpot, R. R., & Shipp, A. M. (2010) · Critical Reviews in Toxicology · doi:10.3109/10408441003667514 · Cited by 292
Ohta, T., Masutomi, N., Tsutsui, N., Sakairi, T., Mitchell, M., Milburn, M. V., Ryals, J. A., Beebe, K. D., & Guo, L. (2009) · Toxicologic Pathology · doi:10.1177/0192623309336152 · Cited by 213
The PPARα-Dependent Rodent Liver Tumor Response Is Not Relevant to Humans: Addressing Misconceptions
Corton, J. C., Peters, J. M., & Klaunig, J. E. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2094-7 · Cited by 175
Molecular mechanisms and genome-wide aspects of PPAR subtype specific transactivation
Bugge, A., & Mandrup, S. (2010) · PPAR Research · doi:10.1155/2010/169506 · Cited by 69
Metadata
- Authors
- Cariello, N. F., Romach, E. H., Colton, H. M., Ni, H., Yoon, L., Falls, J. G., Casey, W., Creech, D., Anderson, S. P., Benavides, G. R., Hoivik, D. J., Brown, R., & Miller, R. T.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-04
- Volume
- 88
- Issue
- 1
- Pages
- 250-264
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2118579582
- Cited by
- 77
- References
- 6
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.